Analysis of hereditary angioedema attacks requiring a second dose of ecallantide-Science-Chemical Encyclopedia-lookchem

Analysis of hereditary angioedema attacks requiring a second dose of ecallantide (cas 460738-38-9)
Add time:07/12/2019 Source:sciencedirect.com

BackgroundEffective treatment of acute attacks is critical in managing hereditary angioedema (HAE). Ecallantide, a plasma kallikrein inhibitor, is approved for the treatment of HAE attacks. Occasionally, a second dose is needed when treating attacks of HAE.

We also recommend Trading Suppliers and Manufacturers of ecallantide (cas 460738-38-9). Pls Click Website Link as below: cas 460738-38-9 suppliers

Prev:Characterization of Anaphylaxis After ecallantide (cas 460738-38-9) Treatment of Hereditary Angioedema Attacks
Next: ecallantide (cas 460738-38-9) for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema: A Multicenter, Randomized, Controlled Trial)

Click to view details

Health and Chemicalmore >